Snapshot from Aug 01, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / BGE-102 Phase 2 trial dosed
Business clinical trial milestone

BGE-102 Phase 2 trial dosed

Analysis based on 8 articles · First reported Jul 14, 2026 · Last updated Jul 14, 2026

Sentiment
40
Attention
3
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Positive sentiment for HitGen and BioAge as BGE-102 advances, potentially validating HitGen's DEL platform and BioAge's pipeline. The trial's success could lead to significant market opportunities in cardiovascular disease.

biotechnology pharmaceutical
Event Summary

HitGen and BioAge Labs announced the dosing of the first participant in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102, a novel oral NLRP3 inhibitor for cardiovascular risk reduction. BGE-102 was developed from a hit identified via HitGen's DEL platform. Topline data are expected in the second half of 2026.

Key Actions
90 BioAge Labs dosed first participant
70 HitGen identified hit compound BioAge Labs
Entities Involved
priv
BioAge Labs
BioAge is advancing its lead candidate BGE-102 into Phase 2, with potential best-in-class profile; positive trial data could boost its valuation.
Importance 90.0 Sentiment 60.0
stock
HitGen
HitGen's DEL platform enabled the discovery of BGE-102; the milestone validates its technology and partnership model.
Importance 80.0 Sentiment 50.0
per
Jin Li
As CEO of HitGen, Jin Li commented positively on the milestone, reflecting leadership in the collaboration.
Importance 30.0 Sentiment 0.0
per
Kristen Fortney
As CEO of BioAge, Fortney highlighted the importance of the Phase 2 milestone and the collaboration with HitGen.
Importance 30.0 Sentiment 0.0
exch
Nasdaq
BioAge is listed on Nasdaq; the event may influence its stock price.
Importance 10.0 Sentiment 0.0
exch
Shanghai Stock Exchange
HitGen is listed on the SSE; the event may influence its stock price.
Importance 10.0 Sentiment 0.0
cnt
United States
BioAge is based in the US; the trial is likely conducted there, but no direct impact.
Importance 5.0 Sentiment 0.0
cnt
United Kingdom
HitGen has a subsidiary in the UK, but no direct impact from this event.
Importance 5.0 Sentiment 0.0
cnt
China
HitGen is headquartered in China, contributing to the country's biotech sector.
Importance 5.0 Sentiment 0.0
Relationships
Nasdaq related ↔ United States
Nasdaq related ↔ United Kingdom
Nasdaq related ↔ China
Shanghai Stock Exchange related ↔ United States
Shanghai Stock Exchange related ↔ China
United States allies ↔ United Kingdom The United States considers the United Kingdom a vital defense ally and significant economic partner, relying on its str
United States strategic rivals ↔ China The United States perceives China as a strategic rival, engaging in an economic and technological competition while also
United Kingdom related ↔ China
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.